AI program predicts bacterial species from urine Gram stain specimens
Official title: Development and Evaluation of AI Program for Predicting Bacterial Species From Urine Gram Stain Specimens
Run by GramEye · NCT06554145 · Data updated 2026-11-12
This study is testing a new AI program that helps doctors quickly and accurately identify bacteria in urine samples to make diagnosing infections easier.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 15000 (estimated) |
| Sponsor | GramEye Industry-sponsored |
| Locations | 1 site (Shinjuku-Ku, Tokyo) |
| Status | Recruiting |
| Started | September 25, 2023 |
| Main results expected | August 2028 |
| Study ends | August 2028 |
| Registry record updated | August 15, 2024 |
| Trial ID | NCT06554145 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients whose urine specimens are being tested for bacterial infections through Gram staining and culture.
✕Probably not a fit
Patients whose urine samples are not suitable for Gram staining or have requested suspension of use may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This research aims to develop an artificial intelligence program that can accurately identify bacterial species from images of Gram-stained urine specimens. The study will evaluate the effectiveness of this AI in improving the accuracy of bacterial identification and reducing the labor involved in the Gram staining process. By automating this aspect of microbiological analysis, the study seeks to enhance diagnostic efficiency in clinical settings.
Why it matters
Potential benefit: If successful, this AI program could significantly improve the speed and accuracy of diagnosing bacterial infections in patients.
How similar studies have gone: While the use of AI in medical diagnostics is a growing field, this specific approach to automating Gram stain analysis is relatively novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Specimens for which urine culture and urine Gram staining tests were performed for clinical purposes Exclusion Criteria: * Samples for which suspension of use has been requested
Where it's running
-
Keio University Hospital
Shinjuku-Ku, Tokyo, Japan Recruiting
Study contacts
- Study coordinator: Tatsuya Yamada, M.D.
- Email: tatsuya.yamada@grameye.com
- Phone: 7028060149
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CTX-187 first-in-human test in healthy people and people with chronic bronchiectasis and Pseudomonas infection
This study tests CTX-187 to see if it is safe and tolerable when given as IV infusions to healthy adults and adults with chronic bronchiectasis and Pseudomonas aeruginosa infection.
-
Personalized beta-lactam dosing in cirrhosis patients with bacterial infections
This study tests whether tailoring beta-lactam dosing based on patient liver disease and drug levels can help people with cirrhosis and bacterial infections.
-
Vaginitis Diagnostic Algorithm Pilot Using Nanopath and Other Tests
This study tests a new Nanopath vaginal test to see if it correctly detects vaginitis-causing pathogens in up to 1,000 people with vaginitis symptoms.
-
Testing single and multiple IV doses of JKN2501 in healthy Chinese adults
This test gives single and multiple intravenous doses of JKN2501 to healthy Chinese adults to see if it's safe and how the body processes it.
-
Tracking acute treatment and long-term outcomes in children with meningitis
This registry will collect care and outcome information to see how current treatments affect short- and long-term outcomes in children under 18 with suspected meningitis in Brazil.
-
Single antibiotic versus two antibiotics for Pseudomonas bone infection
This study will test whether one antibiotic works as well as two for adults with bone infections caused by Pseudomonas aeruginosa.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.